지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a total of 27 patients who received the MCD regimen between April 2011 and November 2013. The MCD regimen consisted of oral melphalan 6.75 mg/m2 on days 1-4, once-weekly dose of oral cyclophosphamide 300 mg/m2 and dexamethasone 20 mg/m2 on days 1-4 and days 15-18. Each cycle was repeated every 28 days. The median age of the patients was 66 years and the MCD regimen was initiated at a median 37.7 months from diagnosis. Patients received a median of five regimens including autologous stem cell transplantation. The overall response rate was 25.9% (very good partial response 3.7%, partial response 22.2%) and 8 (29.6%) patients achieved a minor response. Median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2-8.5) ; overall survival 11.7 months (95% CI, 5.4-16.6). Grade 3 or 4 neutropenia and thrombocytopenia were observed in 51.8% and 33.3%, respectively. Although the overall response rate is relatively low, the MCD regimen may have a role as a bridge to a novel regimen in heavily pretreated patients with MM.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Dimopoulos M / 2007 / Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma / N Engl J Med 357:2123~2132
Anderson KC / 2016 / Progress and paradigms in multiple myeloma / Clin Cancer Res 22:5419~5427
Zago M / 2014 / Lenalidomide in relapsed and refractory multiple myeloma disease:feasibility and benefits of long-term treatment / Ann Hematol 93:1993~1999
Baz RC / 2016 / Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma / Blood 127:2561~2568
Usmani SZ / 2016 / Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma / Blood 128:37~44
Anderson KC / 2016 / Progress and paradigms in multiple myeloma / Clin Cancer Res 22:5419~5427
Zago M / 2014 / Lenalidomide in relapsed and refractory multiple myeloma disease:feasibility and benefits of long-term treatment / Ann Hematol 93:1993~1999
Baz RC / 2016 / Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma / Blood 127:2561~2568
Usmani SZ / 2016 / Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma / Blood 128:37~44
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
Blood Research
2016 .01
-
Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma
Cancer Research and Treatment
2015 .01
-
Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
Cancer Research and Treatment
2023 .04
-
불응성/재발성 다발골수종의 볼테조밉 구제 치료의 실제: 단일 기관의 경험
대한내과학회지
2015 .01
-
Treatment Outcomes in Children and Adolescents with Relapsed or Progressed Solid Tumors: a 20-year, Single-Center Study
Journal of Korean Medical Science
2018 .01
-
21세기 다발골수종의 단일 기관 현실 세계 경험
대한내과학회지
2022 .04
-
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Cancer Research and Treatment
2022 .04
-
Salvage treatment of relapsed/refractory LCH
Blood Research
2016 .01
-
Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis
Korean Journal of Helicobacter Upper Gastrointestinal Research
2021 .01
-
비알콜성 지방간 동물모델에서 갈화추출물의 간보호 효과
대한본초학회지(본초분과학회지)
2018 .01
-
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Cancer Research and Treatment
2020 .01
-
Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
Blood Research
2021 .09
-
Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Exploring the pros and cons of mechanistic case diagrams for problem-based learning
Korean Journal of Medical Education
2017 .01
-
Multiple Myeloma Similar to Traumatic Trigeminal Neuropathy after Dental Treatment: Case Report
Journal of Oral Medicine and Pain
2020 .06
-
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
영남의대학술지
2018 .01
-
다발성 골수종 환자의 삶의 질
성인간호학회지
2016 .06
-
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
Blood Research
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0